Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Neose Technologies, Inc. (NasdaqNM:NTEC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
July 26Conference call: Neose Technologies 2nd Quarter Financial Results
Location
102 Witmer Road
Horsham, PA 19044
Phone: (215) 441-5890
Fax: (215) 441-5896
Email: info@neose.com
Employees (last reported count): 87
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 49%
·Over the last 6 months:
 · one insider buy; 5,000  shares
 · one insider sell; 5,000  shares
·Institutional: 62% (121% of float)
(118 institutions)
·Net Inst. Buying: 44.0K shares (+0.50%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Neose Technologies, Inc. develops proprietary technologies for the synthesis and manufacture of complex carbohydrates. The Company's enzymatic glycosylation technology platform makes feasible the synthesis and modification of a wide range of complex carbohydrates, which are chains of simple sugar molecules that can be joined together in many different combinations. The Company's methods can produce complex carbohydrates that are attached to proteins, as in recombinant therapeutic glycoproteins, are attached to lipids, as in therapeutic cancer vaccines or are solely carbohydrates, as found in human breast milk. The Company's technology is also capable of correcting or completing the human carbohydrate patterns on glycoproteins, potentially resulting in improved pharmacokinetic profile, strengthened patent claims and manufacturing efficiencies.
More from Market Guide: Expanded Business Description

Financial Summary
NTEC is focused on the enzymatic synthesis of complex carbohydrates, and discovers and develops complex carbohydrates for nutritional, pharmaceutical, consumer and industrial uses. For the six months ended 6/01, revenues fell 84% to $604 thousand. Net loss totaled $8.5 million, up from $3.9 million. Revenues reflect the absence of payments received from agreements with Bristol-Myers. Net loss also reflects higher S/G/A expenses due to additional personnel.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Stephen Roth, Ph.D., 58
Chairman, CEO
$389K--  
P. Sherrill Neff, 49
Pres, COO, Chief Financial Officer, Director
381K--  
Eric Sichel, M.D., 42
VP, Bus. Strategy and Corp. Communications
--  --  
David Zopf, M.D., 58
VP of Drug Devel.
239K$148K
Edward McGuire, Ph.D., 63
VP-R&D
204K541K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NTECAs of 31-Aug-2001
Price and Volume
52-Week Low
on 28-Mar-2001
$22.375
Recent Price$42.65 
52-Week High
on 2-Oct-2000
$52.00 
Beta0.41 
Daily Volume (3-month avg)73.5K
Daily Volume (10-day avg)77.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-0.8%
52-Week Change
relative to S&P500
+33.1%
Share-Related Items
Market Capitalization$598.6M
Shares Outstanding14.0M
Float7.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$6.94 
Earnings (ttm)-$0.94 
Earnings (mrq)-$0.37 
Sales (ttm)$0.11 
Cash (mrq)$6.12 
Valuation Ratios
Price/Book (mrq)6.15 
Price/EarningsN/A 
Price/Sales (ttm)400.88 
Income Statements
Sales (ttm)$1.49M
EBITDA (ttm)-$15.2M
Income available to common (ttm)-$13.1M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-11.55%
Return on Equity (ttm)-12.64%
Financial Strength
Current Ratio (mrq)23.49 
Debt/Equity (mrq)0.06 
Total Cash (mrq)$85.9M
Short Interest
As of 8-Aug-2001
Shares Short535.0K
Percent of Float7.4%
Shares Short
(Prior Month)
551.0K
Short Ratio8.63 
Daily Volume62.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.